X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
VERVE-101 is a PCSK9 gene editing program trial was halted, due to safety concerns occured in patients with heterozygous familial hypercholesterolemia.
Lead Product(s): VERVE-101
Therapeutic Area: Genetic Disease Product Name: VERVE-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2024
Details:
The net proceeds will fund the continued clinical development of VERVE-101 and preclinical and clinical development of VERVE-102 and VERVE-201, to conduct research and development activities.
Lead Product(s): VERVE-101
Therapeutic Area: Genetic Disease Product Name: VERVE-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 28, 2023
Details:
VERVE-101 is an investigational, in vivo base editing medicine designed to be a single-course treatment that inactivates the PCSK9 gene in the liver to durably lower blood LDL-C. It is being evaluated for the treatment of heterozygous familial hypercholesterolemia.
Lead Product(s): VERVE-101
Therapeutic Area: Cardiology/Vascular Diseases Product Name: VERVE-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 12, 2023
Details:
Under the terms of the collaboration, Verve will advance the research and development of its preclinical stage in vivo gene editing program targeting lipoprotein(a), an LDL-like particle with apolipoprotein B covalently linked to apolipoprotein(a).
Lead Product(s): Lipoprotein
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $525.0 million Upfront Cash: $60.0 million
Deal Type: Collaboration June 15, 2023
Details:
VERVE-101 is a novel, investigational gene editing medicine that permanently turns off the PCSK9 gene in the liver to reduce disease-driving LDL-C. It is being developed initially as a treatment for patients with heterozygous familial hypercholesterolemia (HeFH)
Lead Product(s): VERVE-101
Therapeutic Area: Genetic Disease Product Name: VERVE-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2023
Details:
The safety profile observed in the first dose cohort with VERVE-101 is encouraging, and in-line with safety data generated with VERVE-101 in the preclinical studies.
Lead Product(s): VERVE-101
Therapeutic Area: Genetic Disease Product Name: VERVE-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 07, 2022
Details:
VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver, a key regulator of cholesterol and triglyceride metabolism, with a precise A-to-G base pair DNA change.
Lead Product(s): VERVE-201
Therapeutic Area: Genetic Disease Product Name: VERVE-201
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2022
Details:
Under the terms of the collaboration, Verve will advance the discovery, research and certain preclinical development of a novel in vivo gene editing program for the target of interest, with all program costs funded by Vertex.
Lead Product(s): In-vivo Gene Editing Medicines
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Vertex Pharmaceuticals
Deal Size: $466.0 million Upfront Cash: $60.0 million
Deal Type: Collaboration July 20, 2022
Details:
VERVE-101 utilizes LNP-mediated delivery to target the liver and base editing technology to make a single A-to-G base change at a specific site in the PCSK9 gene in order to disrupt PCSK9 protein production, which subsequently lowers LDL-C levels in the blood.
Lead Product(s): VERVE-101
Therapeutic Area: Cardiology/Vascular Diseases Product Name: VERVE-101
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2022
Details:
Verve’s lead product candidate, VERVE-101, is designed to turn off the PCSK9 gene in the liver in order to disrupt blood PCSK9 protein production and thereby reduce blood LDL-C levels, with the goal of reducing a patient’s risk for cardiovascular disease.
Lead Product(s): VERVE-101
Therapeutic Area: Genetic Disease Product Name: VERVE-101
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $266.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 28, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
